



Press Release |

IBA AND PROCURE SET RECORD ON DEVELOPMENT OF SECOND PROTON THERAPY CENTER

First Patient Treated 24 Months After Breaking Ground

For immediate release - 16 November 2010

BLOOMINGTON, Ind., U.S.A., and LOUVAIN-LA-NEUVE, Belgium (Nov. 16, 2010) – IBA (Ion Beam Applications S.A.) and ProCure Treatment Centers, Inc., (ProCure) announced today that the CDH Proton Center, *A ProCure Center*, located outside Chicago, recently delivered proton radiation treatment to its first patients using IBA's Proteus 235 proton delivery system. It took only 24 months to build the facility, install the equipment and treat the first patient, setting a new world record in bringing this important technology to patients who could benefit.

Working together, first in developing a center in Oklahoma City and now in suburban Chicago, IBA and ProCure have reduced the timeline for development and construction of a proton therapy center by a full year.

"This is a momentous occasion that represents a major step forward in the treatment of cancer. We are extremely proud of our partnership with ProCure and the results that it has generated," said Pierre Mottet, Chief Executive Officer of IBA. "IBA has demonstrated its continued leadership in the development of proton centers and just as we did following construction of OKC center, we look forward to making this treatment available to even more patients."

"It takes a real team effort to make this happen," said Hadley Ford, Chief Executive Officer of ProCure. "The IBA crew proved itself at our center in OKC, and consistently exceeded our expectations in Chicago. Their expertise and acumen are of great benefit."

The Chicago center is the second proton therapy installation to use inclined beam technology, which was developed by ProCure and IBA as an alternative to a gantry. The inclined beam can treat approximately 80 percent of the tumors treated with a gantry and fits in a space about half the size of a gantry room, allowing the footprint of the proton centers to be much smaller and making construction less costly. The inclined beam also requires less commissioning time and allows for easier maintenance.

IBA is committed to making proton therapy, the most accurate cancer treatment, available worldwide. To date, IBA has been selected to install 22 proton therapy centers, of which 11 are treating patients in Asia, Europe and the U.S., and five are under construction. Altogether, this represents more than half of the clinical-based proton therapy facilities in the world.



Press Release |

Proton therapy is an advanced alternative to X-ray radiation therapy for certain types of cancerous and non-cancerous tumors. Proton therapy has superior dose distribution, depositing the majority of its energy within a precisely controlled range, directly within the tumor, sparing healthy tissues. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, improving outcomes and quality of life for patients. There are only 32 proton therapy centers operating worldwide. The CDH Proton Center, *A ProCure Center*, is a collaboration involving ProCure; Central DuPage Hospital, Winfield, Ill.; and Radiation Oncology Consultants, a 15-physician radiation oncology practice serving hospitals throughout the Chicago area.

The ProCure Proton Therapy Center in Oklahoma City opened in July 2009, 27 months after construction began. To date, the Oklahoma City center has treated more than 250 patients with 51 different cancer diagnoses from 19 states. It is the first proton therapy center in the world to use inclined beam technology.

ABOUT IBA

Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization. Listed on the pan-European stock exchange Euronext, IBA is included in the BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: <http://www.iba-worldwide.com>

Contact

IBA	ProCure
Sandrine Leriche	Sky Opila
VP Corporate Communication	Account Executive
Telephone: +32 10.47.58.90	312-558-1770
InvestorRelations@iba-group.com	sopila@pcipr.com

ABOUT PROCURE

ProCure Treatment Centers, Inc. is a privately held health care company dedicated to improving the lives of patients with cancer by increasing access to proton therapy. The company was founded in 2005 in Bloomington, Ind., and is the first to develop a network of proton therapy centers in cities across the United States. The ProCure Proton Therapy Center in Oklahoma City opened in July 2009 and the CDH Proton Center, *A ProCure Center* opened in October 2010. ProCure's third center is under construction in Somerset, N.J.; and others are in development in Seattle, Detroit and South Florida. ProCure provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of proton therapy centers. ProCure's solution reduces the time, cost and effort necessary to build and operate a facility. ProCure is advancing proton therapy by collaborating with radiation oncology practices and hospitals to develop centers, through innovation and improvements in technology, and by providing training at the world's only educational facility specializing in proton therapy. For more information, visit procure.com.